CMCarol Mao

Carol Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carol Mao has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis

    by Andrew J. Cutler, Anaïs Lemyre, Qiaoyi Zhang, Carol Mao, Todor I. Totev, Marjolaine Gauthier-Loiselle, Yujie Wu, Jingyi Liu, Mahmoud Hashim, Madhav Namjoshi, et al.

    Atypical antipsychotics are common adjunctive therapies for major depressive disorder (MDD) with inadequate antidepressant (ADT) response. In 2025, lumateperone was approved in the US as adjunctive treatment for adults with MDD, and comparative evidence is lacking. This network meta-analysis compared the efficacy and safety of lumateperone with those of other approved atypical antipsychotics for MDD. Registrational randomized clinical trials as documented in US product labeling (RCTs; N = 10; aripiprazole, brexpiprazole, cariprazine, lumateperone, and quetiapine XR) were used to build a star-shaped, 11-treatment-dose node network anchored on placebo + ADT. Outcomes available for ≥ 9 RCTs were considered. Efficacy outcomes comprised change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), MADRS response and remission, and change from baseline in Clinical Global Impression-Severity (CGI-S) scale. Safety outcomes included weight change from baseline, akathisia, and somnolence. A fixed-effect Bayesian approach was applied. Pairwise treatment effects were compared; a probability of superiority > 85% (< 15%) indicated favored (unfavored) treatment. Network-wide treatment ranking was estimated using Surface Under the Cumulative Ranking (SUCRA) curves. Based on MADRS change from baseline, all atypical antipsychotics were favored versus placebo + ADT, with mean difference from placebo highest for lumateperone 42 mg/day (- 4.70). Other efficacy endpoints showed a consistent pattern, with active treatments favored over placebo + ADT across most nodes for response (10/11), remission (6/11), and CGI-S change (10/11). SUCRA ranking placed lumateperone as the treatment with the highest likelihood of being most efficacious across endpoints. Treatments differed in their safety profiles. Lumateperone was the only node with no weight gain relative to placebo and ranked first for weight-related safety outcomes. Lumateperone also ranked better than average for akathisia risk but below average for somnolence risk. Lumateperone represents an effective adjunctive therapy for adult MDD, with no weight change.

  • Open Access

    Health Care Use and Recurrence Rate in Hemolytic Disease of the Fetus and Newborn: Retrospective Cohort Study

    by Nehaa Khadka, Michael J Fassett, Carol Mao, Fagen Xie, Vicki Y Chiu, Jiaxiao M Shi, Theresa M Im, Sunhea Kim, Daniella Park, Darios Getahun

    Background: Hemolytic disease of the fetus and newborn (HDFN) is a life-threatening condition resulting from maternal-fetal erythrocyte antigen incompatibility. Although anti–Rhesus D (RhD) prophylaxis has reduced RhD-associated cases, HDFN persists due to non-RhD antibodies and gaps in prevention. Population-based data on maternal and neonatal outcomes and recurrence patterns are limited. Objective: This study aimed to characterize maternal and neonatal outcomes, health care use patterns, and recurrence rates of HDFN across pregnancies. Methods: We conducted a retrospective cohort study of 464,711 pregnancies within the Kaiser Permanente Southern California system from January 1, 2008, to June 30, 2022. HDFN diagnoses were confirmed using validated natural language processing–assisted manual chart review and followed through 2023. Maternal characteristics, neonatal outcomes, and health care use were compared by HDFN status, and recurrence patterns were evaluated among individuals with ≥2 pregnancies. Chi-square tests and Wilcoxon rank-sum tests were used to compare characteristics between HDFN and non-HDFN pregnancies. Statistical significance was defined as P<.05. Results: Among all pregnancies, 139 of 464,711 (0.03%) were diagnosed with HDFN. Women with HDFN were more likely than those without HDFN to be older (aged ≥35 years; n=42, 30.2% vs n=97,146, 20.9%) and multiparous (n=121, 87.1% vs n=264,766, 57%). Infants affected by HDFN had higher rates of preterm birth (n=40, 28.4% vs n=42,240, 9.5%), low birth weight (<2500 g; n=22, 15.6% vs n=31,740, 7.1%), and neonatal jaundice (n=92, 65.2% vs n=162,465, 36.4%) than non-HDFN infants. Delivery hospitalizations (median 5.0, IQR 2.0-7.5 days vs median 2.0, IQR 1.0-2.0 days) and neonatal intensive care unit stays (median 4.0, IQR 0.0-7.0 days vs median 0.0, IQR 0.0-0.0 days) were longer, and maternal nondelivery hospitalizations were more frequent (n=27, 19.4% vs n=23,228, 5%) among pregnancies complicated by HDFN. Among women with a prior HDFN-affected pregnancy, 83.3% (n=25) experienced recurrence in a subsequent pregnancy. Of these recurrent cases, 32% (n=8) were severe, and 75% (n=6) involved fetal anemia requiring at least 1 intrauterine transfusion. Conclusions: HDFN was rare but was associated with substantial maternal and neonatal morbidity, including higher rates of preterm birth, increased neonatal intensive care unit admissions, and greater health care use. Recurrence was frequent and clinically significant, underscoring the importance of early surveillance and proactive management strategies.

  • Open Access

    Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies

    by Nana A Mensah, Michael J Fassett, Nehaa Khadka, Jiaxiao M Shi, Fagen Xie, Vicki Y Chiu, Theresa M Im, Sunhea Kim, Daniella Park, Carol Mao, et al.

    Background: Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed. Objective: This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system. Methods: We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processing–assisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status. Results: The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse. Conclusions: We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processing–assisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. International Registered Report Identifier (IRRID): DERR1-10.2196/77836


  • Open Access

    Health Care Use and Recurrence Rate in Hemolytic Disease of the Fetus and Newborn: Retrospective Cohort Study (Preprint)

    by Nehaa Khadka, Michael J Fassett, Carol Mao, Fagen Xie, Vicki Y Chiu, Jiaxiao M Shi, Theresa M Im, Sunhea Kim, Daniella Park, Darios Getahun

    BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a life-threatening condition resulting from maternal-fetal erythrocyte antigen incompatibility. Although anti–Rhesus D (RhD) prophylaxis has reduced RhD-associated cases, HDFN persists due to non-RhD antibodies and gaps in prevention. Population-based data on maternal and neonatal outcomes and recurrence patterns are limited. OBJECTIVE This study aimed to characterize maternal and neonatal outcomes, health care use patterns, and recurrence rates of HDFN across pregnancies. METHODS We conducted a retrospective cohort study of 464,711 pregnancies within the Kaiser Permanente Southern California system from January 1, 2008, to June 30, 2022. HDFN diagnoses were confirmed using validated natural language processing–assisted manual chart review and followed through 2023. Maternal characteristics, neonatal outcomes, and health care use were compared by HDFN status, and recurrence patterns were evaluated among individuals with ≥2 pregnancies. Chi-square tests and Wilcoxon rank-sum tests were used to compare characteristics between HDFN and non-HDFN pregnancies. Statistical significance was defined as P<.05. RESULTS Among all pregnancies, 139 of 464,711 (0.03%) were diagnosed with HDFN. Women with HDFN were more likely than those without HDFN to be older (aged ≥35 years; n=42, 30.2% vs n=97,146, 20.9%) and multiparous (n=121, 87.1% vs n=264,766, 57%). Infants affected by HDFN had higher rates of preterm birth (n=40, 28.4% vs n=42,240, 9.5%), low birth weight (<2500 g; n=22, 15.6% vs n=31,740, 7.1%), and neonatal jaundice (n=92, 65.2% vs n=162,465, 36.4%) than non-HDFN infants. Delivery hospitalizations (median 5.0, IQR 2.0-7.5 days vs median 2.0, IQR 1.0-2.0 days) and neonatal intensive care unit stays (median 4.0, IQR 0.0-7.0 days vs median 0.0, IQR 0.0-0.0 days) were longer, and maternal nondelivery hospitalizations were more frequent (n=27, 19.4% vs n=23,228, 5%) among pregnancies complicated by HDFN. Among women with a prior HDFN-affected pregnancy, 83.3% (n=25) experienced recurrence in a subsequent pregnancy. Of these recurrent cases, 32% (n=8) were severe, and 75% (n=6) involved fetal anemia requiring at least 1 intrauterine transfusion. CONCLUSIONS HDFN was rare but was associated with substantial maternal and neonatal morbidity, including higher rates of preterm birth, increased neonatal intensive care unit admissions, and greater health care use. Recurrence was frequent and clinically significant, underscoring the importance of early surveillance and proactive management strategies.

  • Open Access

    Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies (Preprint)

    by Nana A Mensah, Michael J Fassett, Nehaa Khadka, Jiaxiao M Shi, Fagen Xie, Vicki Y Chiu, Theresa M Im, Sunhea Kim, Daniella Park, Carol Mao, et al.

    BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed. OBJECTIVE This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system. METHODS We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processing–assisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status. RESULTS The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse. CONCLUSIONS We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processing–assisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77836